noom with glp-1 Launches Microdose Program, Including Medication and Microhabits Program Microdosing GLP-1 for Weight Loss
Description
Two-layer sustained-release microneedles encapsulating exenatide for type 2 diabetes treatment
The GLP-1 Market is expected to witness substantial growth as pharmaceutical companies accelerate R&D efforts, expand manufacturing capacity, and compete to develop next-generation therapies for obesity and metabolic disorders
[Taking a GLP-1] is not a failure
Using only the injectable subcutaneous formulation
That support made all the difference
As shortages continue, some governments are asking clinicians not to prescribe the drugs for obesity and instead reserve them for people with type 2 diabetes
